TORONTO, Nov. 14 /CNW/ - Cannasat Therapeutics Inc. (CTH: TSXV) and
IntelGenx Corp. today announced a long-term collaborative agreement to
co-develop novel cannabinoid-based products through a combination of
Cannasat's and IntelGenx's proprietary drug delivery technologies. The
collaboration will focus on the development and production of new formulations
of cannabinoid pharmaceutical products, starting with Cannasat's lead product,
CAT 310.
